DOP2015000302A - Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina - Google Patents
Compuestos heteroaromáticos y su uso como ligandos d1 de dopaminaInfo
- Publication number
- DOP2015000302A DOP2015000302A DO2015000302A DO2015000302A DOP2015000302A DO P2015000302 A DOP2015000302 A DO P2015000302A DO 2015000302 A DO2015000302 A DO 2015000302A DO 2015000302 A DO2015000302 A DO 2015000302A DO P2015000302 A DOP2015000302 A DO P2015000302A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- post
- cognitive
- disorder
- compounds
- somnolence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA, EN PARTE, LOS COMPUESTOS DE LA FÓRMULA I: Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS; PROCESOS PARA LA PREPARACIÓN DE; INTERMEDIARIOS UTILIZADOS EN LA PREPARACIÓN DE; Y COMPOSICIONES QUE CONTIENEN LOS COMPUESTOS O SALES, Y SU USOS PARA TRATAR LOS TRASTORNOS MEDIADOS POR D1 (O ASOCIADOS CON D1) QUE INCLUYEN, POR EJEMPLO, ESQUIZOFRENIA (POR EJEMPLO, SUS SÍNTOMAS COGNITIVOS Y NEGATIVOS), DISCAPACIDAD COGNITIVA (POR EJEMPLO, DISCAPACIDAD COGNITIVA ASOCIADA CON ESQUIZOFRENIA, AD, PD, O TERAPIA DE FARMACOTERAPIA), ADHD, IMPULSIVIDAD, JUEGO COMPULSIVO, COMER EN EXCESO, TRASTORNO DEL ESPECTRO DE AUTISMO, MCI, DECLIVE COGNITIVO RELACIONADO CON LA EDAD, DEMENCIA, RLS, ENFERMEDAD DE PARKINSON, COREA DE HUNTINGTON, ANSIEDAD, DEPRESIÓN, MDD, TRD, TRASTORNO BIPOLAR, APATÍA CRÓNICA, ANHEDONIA, FÁTIGA CRÓNICA, TRASTORNO POR ESTRÉS POST-TRAUMÁTICO, TRASTORNO AFECTIVO ESTACIONAL, TRASTORNO DE ANSIEDAD SOCIAL, DEPRESIÓN POST-PARTO, SÍNDROME DE SEROTONINA, DEPENDENCIA DE ABUSO DE SUSTANCIAS Y FÁRMACOS, RECAÍDA POR ABUSO DE FÁRMACOS, SÍNDROME DE TOURETTE, DISQUINESIA TARDÍA, SOMNOLENCIA, SOMNOLENCIA DIURNA EXCESIVA, CAQUEXIA, FALTA DE ATENCIÓN, DISFUNCIÓN SEXUAL, MIGRAÑA, SLE, HIPERGLICEMIA, ATEROSCLEROSIS, DISLIPIDEMIA, OBESIDAD, DIABETES, SEPSIS, NECROSIS TUBULAR POST-ISQUÉMICA, FALLA RENAL, HIPONATREMIA, EDEMA RESISTENTE, NARCOLEPSIA, HIPERTENSIÓN, FALLA CARDIACA CONGESTIVA, HIPOTONIA OCULAR POSTOPERATIVA, TRASTORNOS DEL SUEÑO, Y DOLOR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840144P | 2013-06-27 | 2013-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2015000302A true DOP2015000302A (es) | 2016-02-29 |
Family
ID=51205521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2015000302A DOP2015000302A (es) | 2013-06-27 | 2015-12-18 | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina |
Country Status (42)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150291625A1 (en) | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
| JP6026024B2 (ja) | 2013-06-27 | 2016-11-16 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 |
| WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CA2946471C (en) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands |
| PE20170009A1 (es) * | 2014-04-25 | 2017-03-17 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 |
| EP3137454A1 (en) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| WO2015166366A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| CN111153859B (zh) * | 2015-04-15 | 2021-09-03 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| DK3389727T3 (da) | 2015-12-18 | 2020-11-02 | Janssen Pharmaceutica Nv | Radioaktivt mærkede mglur2/3-pet-ligander |
| ES2820823T3 (es) | 2015-12-18 | 2021-04-22 | Janssen Pharmaceutica Nv | Ligandos PET mGluR2/3 radiomarcados |
| JP6929857B2 (ja) | 2016-01-15 | 2021-09-01 | ファイザー・インク | ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド |
| MA43761A (fr) | 2016-03-24 | 2021-05-05 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj |
| SI3438095T1 (sl) | 2016-03-30 | 2021-09-30 | Ishihara Sangyo Kaisha, Ltd. | Piridazinonska spojina ali njena sol in herbicid, ki jo vsebuje |
| CN108530310A (zh) * | 2017-03-02 | 2018-09-14 | 中国科学院上海药物研究所 | 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用 |
| JP2023522949A (ja) | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Ｃｄ７３調節のための化合物及び方法並びにそれらの表示 |
| WO2023102087A1 (en) | 2021-12-03 | 2023-06-08 | Teva Czech Industries S.R.O | Solid state forms of tavapadon and processes for preparation thereof |
| WO2023143321A1 (zh) * | 2022-01-29 | 2023-08-03 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5025142B1 (es) | 1969-07-30 | 1975-08-21 | ||
| JPS5039272B1 (es) | 1970-07-14 | 1975-12-16 | ||
| JPS5025142A (es) | 1973-07-06 | 1975-03-17 | ||
| JPS5039272A (es) | 1973-08-10 | 1975-04-11 | ||
| JPS5516432B2 (es) | 1974-05-28 | 1980-05-01 | ||
| JPS51113899A (en) | 1975-03-27 | 1976-10-07 | Yoshitomi Pharmaceut Ind Ltd | Method for preparing novel tetrazole derivatives |
| JPS522031A (en) | 1975-06-24 | 1977-01-08 | Japan Niyuupureito Hokushiyou | Sunshade device |
| DE2861615D1 (en) | 1978-01-02 | 1982-03-11 | Ciba Geigy Ag | Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides |
| EP0101662A3 (de) | 1982-06-25 | 1985-12-04 | Ciba-Geigy Ag | Benzoylparabansäuren |
| US4550108A (en) | 1983-08-17 | 1985-10-29 | Ciba Geigy Corporation | 1,3,5-Oxadiazine-2,4-diones and pesticidal use |
| US4723015A (en) | 1983-10-17 | 1988-02-02 | Ciba-Geigy Corporation | Certain insecticidal N-2-pyridyloxyphenylbenzimidates |
| IL73611A0 (en) | 1983-12-06 | 1985-02-28 | Nippon Soda Co | 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides |
| JPS61275271A (ja) | 1985-05-30 | 1986-12-05 | Nippon Soda Co Ltd | １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤 |
| DE3545786A1 (de) | 1985-12-21 | 1987-06-25 | Schering Ag | Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung |
| DE3545569A1 (de) | 1985-12-21 | 1987-06-25 | Hoechst Ag | Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel |
| DE3631511A1 (de) | 1986-09-12 | 1988-03-24 | Schering Ag | 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel |
| EP0296518A1 (de) | 1987-06-22 | 1988-12-28 | Ciba-Geigy Ag | Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung |
| DE3826855A1 (de) * | 1988-08-06 | 1990-02-15 | Cassella Ag | 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung |
| JPH0259573A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ２（１ｈ）−ピリミジノン誘導体又はその塩類 |
| JPH0259574A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ピラジノン誘導体又はその塩類 |
| US5066667A (en) | 1989-06-26 | 1991-11-19 | Ciba-Geigy Corporation | Thioxotetrazolines and insecticidal use thereof |
| EP0438209B1 (en) | 1990-01-18 | 1994-09-21 | Nissan Chemical Industries, Limited | Uracil derivatives and pesticides containing the same as active ingredient |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH03261783A (ja) | 1990-03-12 | 1991-11-21 | Suntory Ltd | １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤 |
| DE4030042A1 (de) | 1990-05-17 | 1991-11-21 | Bayer Ag | Verwendung von substituierten 1,2,4-triazindionen |
| JP3018422B2 (ja) | 1990-07-27 | 2000-03-13 | 日東紡績株式会社 | 床 材 |
| US5630962A (en) | 1990-12-19 | 1997-05-20 | Hoechst Aktiengesellschaft | 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures |
| JPH0539272A (ja) | 1991-01-09 | 1993-02-19 | Nissan Chem Ind Ltd | ピリミジンジオン誘導体および除草剤 |
| JPH0525142A (ja) | 1991-07-12 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
| JPH05202031A (ja) | 1992-01-28 | 1993-08-10 | Nissan Chem Ind Ltd | Ｎ−アミノピリミジンジオン誘導体および除草剤 |
| EP0630370A1 (en) | 1992-03-11 | 1994-12-28 | E.I. Du Pont De Nemours And Company | Fungicidal oxazolidinones |
| US5482951A (en) | 1992-05-29 | 1996-01-09 | Kumiai Chemical Industry Co., Ltd. | Triazole derivatives as well as insecticide and acaricide |
| JPH07501084A (ja) | 1992-08-31 | 1995-02-02 | チバ−ガイギー アクチェンゲゼルシャフト | ４，５−ジシアノイミダゾール誘導体及びそれらを含む農薬（ｐｅｓｔｉｃｉｄａｌ）組成物 |
| AU673881B2 (en) | 1992-12-25 | 1996-11-28 | Nippon Soda Co., Ltd. | Heterocyclic derivative and pest control agent |
| JP3261783B2 (ja) | 1993-02-04 | 2002-03-04 | ミノルタ株式会社 | 光変調素子 |
| JP3682075B2 (ja) | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| EP0712847A4 (en) | 1993-08-11 | 1997-05-28 | Nippon Soda Co | IMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A PEST CONTROL |
| JPH0873446A (ja) | 1994-04-22 | 1996-03-19 | Nippon Soda Co Ltd | ヘテロ環化合物および殺虫・殺ダニ剤 |
| JPH0827120A (ja) | 1994-07-08 | 1996-01-30 | Nissan Chem Ind Ltd | テトラヒドロピリミジノン誘導体 |
| JPH08217777A (ja) | 1995-02-10 | 1996-08-27 | Nippon Nohyaku Co Ltd | ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤 |
| DE19518681A1 (de) | 1995-05-22 | 1996-11-28 | Bayer Ag | Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JPH09291282A (ja) | 1996-04-26 | 1997-11-11 | Sumitomo Chem Co Ltd | 安定化した液晶材料およびこれを用いた液晶素子 |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2001521027A (ja) * | 1997-10-27 | 2001-11-06 | アイエスケー・アメリカズ・インコーポレーティッド | 置換ベンゼン化合物、それらの製造方法並びにそれらを含有する除草剤組成物及び落葉剤組成物 |
| US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
| AU1130700A (en) | 1998-10-23 | 2000-05-15 | Dow Agrosciences Llc | Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles |
| GB9903671D0 (en) | 1999-02-17 | 1999-04-14 | Cenes Ltd | Dopamine D-1 receptor agonist compounds |
| BR0107662A (pt) | 2000-01-18 | 2002-11-19 | Pfizer Prod Inc | Antagonistas do fator de liberação de corticotropina |
| MXPA02009763A (es) | 2000-04-04 | 2003-03-27 | Shionogi & Co | Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa. |
| US6599926B2 (en) | 2000-06-23 | 2003-07-29 | Bristol-Myers Squibb Company | Heteroaryl-phenyl substituted factor Xa inhibitors |
| US6476055B1 (en) | 2001-03-28 | 2002-11-05 | Nippon Soda Co. Ltd. | 5,5-disubstituted thiazolidine derivative pesticides |
| US7501429B2 (en) | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
| BR0209499A (pt) | 2001-05-09 | 2004-07-06 | Sumitomo Chem Takeda Agro Co | Composto, processo para produzir o composto, e, composição pesticida |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| AU2003261713A1 (en) | 2002-08-26 | 2004-03-11 | Nissan Chemical Industries, Ltd. | Substituted benzanilide compound and pest control agent |
| AU2003276201A1 (en) | 2002-11-11 | 2004-06-03 | Bayer Healthcare Ag | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist |
| US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| US6969744B2 (en) | 2003-06-19 | 2005-11-29 | University Of Southern Mississippi | Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation |
| BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| JP4451849B2 (ja) | 2003-11-28 | 2010-04-14 | 日本曹達株式会社 | アリール複素環誘導体および農園芸用殺菌剤および殺虫剤 |
| JP2005272452A (ja) | 2004-02-23 | 2005-10-06 | Nissan Chem Ind Ltd | 置換ベンズアニリド化合物及び有害生物防除剤 |
| US20090036495A1 (en) | 2004-04-20 | 2009-02-05 | Pfizer, Inc. | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
| WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| TW200612827A (en) | 2004-08-25 | 2006-05-01 | Sumitomo Chemical Co | Insecticide composition |
| JP5301991B2 (ja) * | 2005-07-29 | 2013-09-25 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体 |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| GB0524786D0 (en) | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| CN101384568B (zh) | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| JP5025142B2 (ja) | 2006-02-27 | 2012-09-12 | 株式会社東芝 | モータ制御装置 |
| AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| AU2007246172A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
| TW200817364A (en) | 2006-09-21 | 2008-04-16 | Nicholas Piramal India Ltd | Compounds for the treatment of metabolic disorders |
| US20090318465A1 (en) | 2006-09-21 | 2009-12-24 | Rosalind Adaikalasamy Marita | Method for identifying compounds that act as insulin-sensitizers |
| KR101504669B1 (ko) | 2006-10-19 | 2015-03-20 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| EP1916240A1 (en) | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Pyridazine derivatives |
| DE102007003036A1 (de) | 2006-12-20 | 2008-06-26 | Bayer Cropscience Ag | Pyrimidinylpyrazole |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| CA2677949C (en) | 2007-02-22 | 2016-02-09 | Paul Anthony Worthington | Iminipyridine derivatives and their uses as microbiocides |
| AR065622A1 (es) | 2007-03-07 | 2009-06-17 | Ortho Mcneil Janssen Pharm | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| CN101294257B (zh) | 2007-04-23 | 2014-06-18 | 株式会社神户制钢所 | 焊接热影响部的韧性优异的钢材及其制造方法 |
| JP2009062290A (ja) | 2007-09-04 | 2009-03-26 | Takeda Chem Ind Ltd | シクロプロパン化合物 |
| TW200922566A (en) * | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| AU2008320875B2 (en) | 2007-10-31 | 2013-08-01 | Abbvie Deutschland Gmbh & Co Kg | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2274280A2 (en) | 2008-04-16 | 2011-01-19 | Biolipox AB | Bis-aryl compounds for use as medicaments |
| US20110112193A1 (en) | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| AU2009262241B2 (en) | 2008-06-25 | 2014-05-22 | Forum Pharmaceuticals Inc. | 1, 2 disubstituted heterocyclic compounds |
| CA2736970A1 (en) * | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivatives for use as medicaments |
| WO2010064688A1 (ja) | 2008-12-03 | 2010-06-10 | 日本農薬株式会社 | ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法 |
| WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| JP5053459B2 (ja) | 2009-01-12 | 2012-10-17 | アイカジェン， インコーポレイテッド | スルホンアミド誘導体 |
| EP2246335A1 (de) | 2009-02-17 | 2010-11-03 | Bayer CropScience AG | Aminopyrimidinamide als Schädlingsbekämpfungsmittel |
| AU2011223888B2 (en) * | 2010-03-04 | 2015-07-02 | Merck Sharp & Dohme Llc | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
| US8927561B2 (en) | 2010-04-23 | 2015-01-06 | Kineta, Inc. | Pyrimidinedione anti-viral compounds |
| KR20120018236A (ko) | 2010-07-23 | 2012-03-02 | 현대약품 주식회사 | 치환된 피리미디닐 유도체 및 이의 제조방법 |
| CN103180326B (zh) | 2010-08-10 | 2015-06-10 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| CN103153955A (zh) | 2010-09-17 | 2013-06-12 | 普渡制药公司 | 吡啶化合物及其用途 |
| ME02873B (me) * | 2011-09-02 | 2018-04-20 | Purdue Pharma Lp | Pirimidini kao blokatori natrijumskog kanala |
| UA111687C2 (uk) | 2012-11-08 | 2016-05-25 | Пфайзер Інк. | Гетероароматичні сполуки як ліганди допаміну d1 |
| US20150291625A1 (en) * | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
| WO2014119770A1 (ja) * | 2013-01-30 | 2014-08-07 | 住友化学株式会社 | ピリダジノン化合物及びそれを含有する除草剤 |
| JP6026024B2 (ja) * | 2013-06-27 | 2016-11-16 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 |
-
2014
- 2014-06-13 JP JP2015563113A patent/JP6026024B2/ja active Active
- 2014-06-13 MA MA38661A patent/MA38661A1/fr unknown
- 2014-06-13 PL PL18180416.2T patent/PL3421462T3/pl unknown
- 2014-06-13 MX MX2020013099A patent/MX2020013099A/es unknown
- 2014-06-13 RS RS20190843A patent/RS59018B1/sr unknown
- 2014-06-13 MX MX2015017169A patent/MX2015017169A/es unknown
- 2014-06-13 EP EP18180416.2A patent/EP3421462B1/en active Active
- 2014-06-13 DK DK18180416.2T patent/DK3421462T3/da active
- 2014-06-13 CU CUP2015000180A patent/CU24334B1/es unknown
- 2014-06-13 TR TR2019/07981T patent/TR201907981T4/tr unknown
- 2014-06-13 EA EA201592146A patent/EA028637B1/ru unknown
- 2014-06-13 PE PE2015002614A patent/PE20160664A1/es unknown
- 2014-06-13 HU HUE18180416A patent/HUE062265T2/hu unknown
- 2014-06-13 ES ES14739554T patent/ES2729630T3/es active Active
- 2014-06-13 WO PCT/IB2014/062217 patent/WO2014207601A1/en active Application Filing
- 2014-06-13 AU AU2014300673A patent/AU2014300673B2/en active Active
- 2014-06-13 NZ NZ713762A patent/NZ713762A/en not_active IP Right Cessation
- 2014-06-13 ES ES18180416T patent/ES2948192T3/es active Active
- 2014-06-13 PT PT181804162T patent/PT3421462T/pt unknown
- 2014-06-13 CA CA2916653A patent/CA2916653C/en active Active
- 2014-06-13 KR KR1020157036343A patent/KR101781723B1/ko active IP Right Grant
- 2014-06-13 SG SG11201509186TA patent/SG11201509186TA/en unknown
- 2014-06-13 UA UAA201510712A patent/UA112945C2/uk unknown
- 2014-06-13 PL PL14739554T patent/PL3013813T3/pl unknown
- 2014-06-13 HR HRP20230546TT patent/HRP20230546T1/hr unknown
- 2014-06-13 AP AP2015008844A patent/AP2015008844A0/xx unknown
- 2014-06-13 CN CN201480036014.7A patent/CN105324376B/zh active Active
- 2014-06-13 PT PT14739554T patent/PT3013813T/pt unknown
- 2014-06-13 EP EP14739554.5A patent/EP3013813B1/en active Active
- 2014-06-13 BR BR122023004130-5A patent/BR122023004130B1/pt active IP Right Grant
- 2014-06-13 DK DK14739554.5T patent/DK3013813T3/da active
- 2014-06-13 MD MDA20150122A patent/MD20150122A2/ro not_active Application Discontinuation
- 2014-06-13 RS RS20230446A patent/RS64342B1/sr unknown
- 2014-06-13 TN TN2015000547A patent/TN2015000547A1/fr unknown
- 2014-06-13 HU HUE14739554A patent/HUE043705T2/hu unknown
- 2014-06-13 FI FIEP18180416.2T patent/FI3421462T3/fi active
- 2014-06-23 US US14/311,963 patent/US9527831B2/en active Active
- 2014-06-24 TW TW103121727A patent/TWI508957B/zh active
- 2014-06-26 UY UY0001035628A patent/UY35628A/es not_active Application Discontinuation
- 2014-06-26 AR ARP140102420A patent/AR096748A1/es unknown
-
2015
- 2015-03-04 US US14/638,608 patent/US9139561B2/en active Active
- 2015-03-04 US US14/638,677 patent/US9107923B2/en active Active
- 2015-10-30 PH PH12015502502A patent/PH12015502502A1/en unknown
- 2015-11-05 IL IL242480A patent/IL242480B/en active IP Right Grant
- 2015-11-09 ZA ZA2015/08252A patent/ZA201508252B/en unknown
- 2015-12-03 CR CR20150634A patent/CR20150634A/es unknown
- 2015-12-18 DO DO2015000302A patent/DOP2015000302A/es unknown
- 2015-12-22 NI NI201500179A patent/NI201500179A/es unknown
- 2015-12-22 GT GT201500350A patent/GT201500350A/es unknown
- 2015-12-24 CL CL2015003735A patent/CL2015003735A1/es unknown
-
2016
- 2016-01-22 EC ECIEPI20163103A patent/ECSP16003103A/es unknown
- 2016-03-23 HK HK16103425.1A patent/HK1215435A1/zh unknown
- 2016-11-11 US US15/349,075 patent/US9822097B2/en active Active
-
2017
- 2017-10-10 US US15/729,111 patent/US10093655B2/en active Active
-
2018
- 2018-09-06 US US16/123,072 patent/US10421744B2/en active Active
-
2019
- 2019-06-27 HR HRP20191163TT patent/HRP20191163T1/hr unknown
- 2019-08-13 US US16/539,865 patent/US10696658B2/en active Active
-
2020
- 2020-05-21 US US16/880,632 patent/US11014909B2/en active Active
-
2021
- 2021-03-17 US US17/204,095 patent/US11964961B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000302A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| NI201500066A (es) | ||
| CL2019001626A1 (es) | Inhibidores de pequeñas moléculas de la familia jak de quinasas. | |
| DOP2015000185A (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| CL2012001397A1 (es) | Compuestos hetero-triciclicos condensados, moduladores de quinasa jak; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la prepararcion de medicamentos utiles en el tratamiento de enfermedades autoinmunes, cancer y trastornos del sistema nervioso central, entre otras. | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CL2016001578A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c. | |
| CO6660505A2 (es) | Compuestos heterocíclicos, su preparación y su aplicación terapéutica | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| CL2016000677A1 (es) | Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2. | |
| AR090085A1 (es) | USO DE COMPUESTOS DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE GLUCOGENO SINTASA CINASA 3 b | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CL2016002064A1 (es) | Derivados de etinilo. | |
| EA201491291A1 (ru) | АГОНИСТЫ mGlu 2/3 | |
| PL413428A1 (pl) | Pochodna benzotiofenopiperazyny i jej zastosowanie | |
| CL2012000650A1 (es) | Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras. |